Pulmonology Articles

Pulmonology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Chen T et al. - Rivaroxaban is a novel oral direct factor Xa inhibitor. Rivaroxaban has been shown to have tolerable adverse effects and a low potential for drug-drug or drug-food interactions. It has the major advantages of once daily oral dosing and no required laboratory monitoring, giving it the potential to replace current antithrombotics in the market today.

Today in CV/Thromboembolic...keeping you current

Graded contrast echocardiography in pulmonary arteriovenous malformations
European Respiratory Journal , 12/16/09

Pulmonary vein stenosis: Case report and literature review
Canadian Respiratory Journal, 12/16/09

Carotid body and cardiorespiratory alterations in intermittent hypoxia: the oxidative link
European Respiratory Journal , 12/15/09

Today in Clinical Pharmacology...keeping you current

Community-acquired upper respiratory tract infections and the role of third-generation oral cephalosporins
Expert Review of Anti-infective Therapy, 12/17/09

Oral Immunotherapy with inactivated NTHi reduces severity of acute exacerbations in severe COPD
Chest, 12/16/09

Use of oseltamivir in children
Canadian Family Physician, 12/16/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address